AG Platkin: Eight Opioid Drug Makers Agree to Pay $720 Million In Nationwide Settlements

Platkin in his appearance today.

 

AG Platkin: Eight Opioid Drug Makers Agree to Pay $720 Million In Nationwide Settlements

New Jersey Could Receive up to $19.8 Million

TRENTON Attorney General Matthew J. Platkin today announced approximately $720 million in nationwide settlements with eight drug makers that manufactured opioid products and worsened the nationwide opioid crisis.

Based on the overwhelming participation by attorneys general across the country, all eight defendants have agreed to proceed with a sign-on period for local governments. New Jersey and its eligible subdivisions could receive up to $19.8 million in all.

“The harms caused by the proliferation of opioids continue to reverberate and New Jersey residents deserve to see these companies held to account,” said Attorney General Platkin. “We expect State partners to use these funds responsibly to alleviate the suffering in the wake of this manmade substance use disorder epidemic.”

The eight defendants and the total amount they will pay in nationwide funds to address the opioid crisis as part of the deal are:

·    Mylan (now part of Viatris): $284,447,916 paid over nine years

·    Hikma: $95,818,293 paid over one to four years

·    Amneal: $71,751,010 paid over 10 years

·    Apotex: $63,682,369 paid in a single year

·    Indivior: $38,022,450 paid over four years

·    Sun: $30,992,087 paid over one to four years

·    Alvogen: $18,680,162 paid in a single year

·    Zydus: $14,859,220 paid in a single year

In addition to these abatement payments, several of the settlements allow states to receive free medication-assisted treatment or cash in lieu of product. Additionally, the seven companies that directly manufacture opioids are prohibited from promoting or marketing opioids and opioid products, making or selling any product that contains more than 40 mg of oxycodone per pill, and are required to put in place a monitoring and reporting system for suspicious orders. Indivior has agreed to not manufacture or sell opioid products for the next 10 years, but it will be able to continue marketing and selling medications to treat opioid use disorder.

Assistant Attorney General Lara Fogel and Deputy Attorney General Brian DeVito of the Division of Law’s Affirmative Civil Enforcement Practice Group handled these settlements on behalf of the State.

 

###

 

News From Around the Web

The Political Landscape